Frequency Of Hyperuricemia In Acute Exacerbation Of Chronic Obstructive Pulmonary Disease

Original Article

Abstract

Background: hyperuricemia as important biomarker for chronic obstructive pulmonary disease (COPD) cases which flare up. High levels of serum uric acid show a relationship with worse inflammation together with higher levels of oxidative stress and hypoxia which make AE-COPD more severe. The evaluation of hyperuricemia occurrence in AE-COPD helps doctors understand both treatment approaches and patient prediction outcomes.

Objectives: The study investigated both the prevalence of hyperuricemia in AE-COPD patients together with its impact on clinical characteristics and hospitalization period and treatment results.

Study design: A Cross-Sectional Study.

Place and duration of study. Department of Pulmonology PAF Hospital Islamabad from jan 2023 to Dec 2023

Methods: This study analyzed 131 patients to evaluate the association between serum uric acid (SUA) levels and clinical outcomes during hospitalization. Hyperuricemia was defined as SUA ≥7 mg/dL for men and ≥6 mg/dL for women. Demographic and clinical characteristics including age, gender, smoking status, and comorbidities were recorded. Statistical analysis was performed using SPSS, with continuous variables reported as mean ± standard deviation. P-values <0.05 were considered statistically significant.

Results: 131 patients who averaged 67.5 ± 8.2 years in age. The Study showed that hyperuricemia affected 45% of all patients under study. Patients experiencing hyperuricemia needed an average of 7.8 ± 2.4 days in hospital compared to the 5.6 ± 1.9 day stay of patients who did not have hyperuricemia. This difference was proven statistically significant (p < 0.05). Patients with hyperuricemia experienced both more severe disease exacerbations and elevated hospital mortalities according to the study findings (p = 0.03 and p = 0.04 respectively). Both age group and gender composition showed no appreciable distinction when comparing individuals with normal uric acid levels to those with elevated levels (p > 0.05).

Conclusion: Hospitalized AE-COPD patients with hyperuricemia experience longer admissions together with more serious exacerbations which lead to increased mortality rates. Risk assessment for AE-COPD patients can benefit from serum uric acid levels which function as an effective biomarker for clinical management. Research requires additional investigation to discover therapeutic applications.